Patents by Inventor Amy E. Wright

Amy E. Wright has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of manzamine compounds in anti-cancer therapeutic regimens
    Patent number: 8691801
    Abstract: Manzamine compounds have been discovered to decrease cell dissociation and cell migration associated with the metastatic potential of cancer cells and a restoration of cancer cell susceptibility to agents, such as TRAIL, which can induce apoptosis. Specifically, Manzamine A has a formerly unrecognized utility in both blocking tumor cell invasion and tumor metastasis as well in restoring cancer cell susceptibility to standard chemotherapeutic agents which induce apoptosis and, therefore, has utility in treating cancer.
    Type: Grant
    Filed: July 17, 2012
    Date of Patent: April 8, 2014
    Assignee: Florida Atlantic University Board of Trustees
    Inventors: Esther A. Guzman, Jacob D. Johnson, Amy E. Wright
  • Use of Manzamine Compounds in Anti-Cancer Therapeutic Regimens
    Publication number: 20120289533
    Abstract: Manzamine compounds have been discovered to decrease cell dissociation and cell migration associated with the metastatic potential of cancer cells and a restoration of cancer cell susceptibility to agents, such as TRAIL, which can induce apoptosis. Specifically, Manzamine A has a formerly unrecognized utility in both blocking tumor cell invasion and tumor metastasis as well in restoring cancer cell susceptibility to standard chemotherapeutic agents which induce apoptosis and, therefore, has utility in treating cancer.
    Type: Application
    Filed: July 17, 2012
    Publication date: November 15, 2012
    Inventors: Esther A. Guzman, Jacob D. Johnson, Amy E. Wright
  • Use of manzamine compounds in anti-cancer therapeutic regimens
    Patent number: 8232266
    Abstract: Manzamine compounds have been discovered to decrease cell dissociation and cell migration associated with the metastatic potential of cancer cells and a restoration of cancer cell susceptibility to agents, such as TRAIL, which can induce apoptosis. Specifically, Manzamine A has a formerly unrecognized utility in both blocking tumor cell invasion and tumor metastasis as well in restoring cancer cell susceptibility to standard chemotherapeutic agents which induce apoptosis and, therefore, has utility in treating cancer.
    Type: Grant
    Filed: February 20, 2007
    Date of Patent: July 31, 2012
    Assignee: Florida Atlantic University Board of Trustees
    Inventors: Esther A. Guzman, Jacob D. Johnson, Amy E. Wright
  • Biologically active aphrocallistin compounds
    Patent number: 8058430
    Abstract: The subject invention provides novel compositions of biologically active compounds which can advantageously be used in blocking cellular proliferation and/or treatment of cancer.
    Type: Grant
    Filed: June 30, 2008
    Date of Patent: November 15, 2011
    Assignee: Florida Atlantic University Broad of Trustees
    Inventors: Amy E. Wright, Susan H. Sennett, Shirley A. Pomponi, Peter J. McCarthy, Esther A. Guzman
  • Antiproliferative activity of the leiodermatolide class of macrolides
    Patent number: 7626043
    Abstract: The subject invention provides novel biologically active compounds that have utility for use in inhibiting cellular proliferation. Pharmaceutical compositions comprising these compounds are also provided. In a specific embodiment, the compounds and compositions of the subject invention can be used in the treatment of cancer.
    Type: Grant
    Filed: August 6, 2007
    Date of Patent: December 1, 2009
    Assignee: Florida Atlantic University Board of Trustees
    Inventors: Amy E. Wright, John K. Reed, Jill Roberts, Ross E. Longley
  • Biologically active lasonolide compounds
    Patent number: 7521474
    Abstract: The subject invention provides novel compositions of biologically active macrolide compounds which can advantageously be used in blocking cellular proliferation, treatment of cancer, treatment of fungal infections and control of spoilage of food, cosmetic and other consumer items.
    Type: Grant
    Filed: July 27, 2006
    Date of Patent: April 21, 2009
    Assignee: Florida Atlantic University Board of Trustees
    Inventors: Amy E. Wright, Shirley A. Pomponi, Peter J. McCarthy, Ying Chen, Ross E. Longley
  • Biologically Active Aphrocallistin Compounds
    Publication number: 20090005400
    Abstract: The subject invention provides novel compositions of biologically active compounds which can advantageously be used in blocking cellular proliferation and/or treatment of cancer.
    Type: Application
    Filed: June 30, 2008
    Publication date: January 1, 2009
    Inventors: Amy E. Wright, Susan H. Sennett, Shirley A. Pomponi, Peter J. McCarthy, Esther A. Guzman
  • Biologically active neopeltolide compounds
    Patent number: 7179828
    Abstract: The subject invention provides novel compositions of biologically active macrolide compounds which can advantageously be used in blocking cellular proliferation, treatment of cancer, treatment of fungal infections and control of spoilage of food, cosmetic and other consumer items.
    Type: Grant
    Filed: June 22, 2004
    Date of Patent: February 20, 2007
    Inventors: Amy E. Wright, Shirley A. Pomponi, Peter J. McCarthy
  • Biologically active lasonolide compounds
    Patent number: 7115756
    Abstract: The subject invention provides novel compositions of biologically active macrolide compounds which can advantageously be used in blocking cellular proliferation, treatment of cancer, treatment of fungal infections and control of spoilage of food, cosmetic and other consumer items.
    Type: Grant
    Filed: June 23, 2004
    Date of Patent: October 3, 2006
    Assignee: Harbor Branch Oceanographic Institution, Inc.
    Inventors: Amy E. Wright, Shirley A. Pomponi, Peter J. McCarthy, Ying Chen, Ross E. Longley
  • Biologically active raspailamide compounds
    Patent number: 7094803
    Abstract: The subject invention provides novel compositions of biologically active polyketide compounds that can advantageously be used in blocking cellular proliferation and treatment of cancer.
    Type: Grant
    Filed: July 12, 2004
    Date of Patent: August 22, 2006
    Assignee: Harbor Branch Oceanographic Institution, Inc.
    Inventors: K. Brian Killday, Amy E. Wright, Shirley A. Pomponi, Ross E. Longley
  • Lactone compounds and methods of use
    Patent number: 7053118
    Abstract: The subject invention provides novel compositions of biologically active compounds which can advantageously be used for inhibiting pathological cellular proliferation. The compounds of the subject invention have utility for use in the treatment of cancer, including tumors.
    Type: Grant
    Filed: March 6, 2003
    Date of Patent: May 30, 2006
    Assignee: Harbor Branch Oceanographic Institution, Inc.
    Inventors: Sarath P. Gunasekera, Ross E. Longley, Amy E. Wright, John K. Reed
  • Biologically active linderazulene terpenes
    Patent number: 6852754
    Abstract: The subject invention provides novel compositions of biologically active linderazulene terpene compounds which can advantageously be used for treating cancer and stopping cell proliferation.
    Type: Grant
    Filed: January 22, 2004
    Date of Patent: February 8, 2005
    Assignee: Harbor Branch Oceanographic Institution, Inc.
    Inventors: Amy E. Wright, Ross E. Longley, Srinivasa Reddy Natala, John K. Reed
  • Biologically active neopeltolide compounds
    Publication number: 20040266847
    Abstract: The subject invention provides novel compositions of biologically active macrolide compounds which can advantageously be used in blocking cellular proliferation, treatment of cancer, treatment of fungal infections and control of spoilage of food, cosmetic and other consumer items.
    Type: Application
    Filed: June 22, 2004
    Publication date: December 30, 2004
    Inventors: Amy E. Wright, Shirley A. Pomponi, Peter J. McCarthy
  • Discorhabdin compounds and methods of use
    Patent number: 6835736
    Abstract: The subject invention provides novel compositions of biologically active discorhabdin compounds which can advantageously be used for inhibiting pathological cellular proliferation. The compounds of the subject invention have utility for use in the treatment of cancer, including tumors.
    Type: Grant
    Filed: February 28, 2003
    Date of Patent: December 28, 2004
    Assignee: Harbor Branch Oceanographic Institution, Inc.
    Inventors: Sarath P. Gunasekera, Ross E. Longley, Shirley A. Pomponi, Amy E. Wright
  • Biologically active pregnene compounds
    Patent number: 6784160
    Abstract: The subject invention provides novel compositions of biologically active glycosylated pregnene compounds which can advantageously be used for treating cancer and stopping cell proliferation.
    Type: Grant
    Filed: April 9, 2003
    Date of Patent: August 31, 2004
    Assignee: Harbor Branch Oceanographic Institution, Inc.
    Inventors: Amy E. Wright, John K. Reed, Ross E. Longley
  • Compositions and uses of dictyostatin compounds
    Patent number: 6677370
    Abstract: Dictyostatin-1 has been found to stabilize microtubules and prohibit their depolymerization to free tubulin. Because of these activities, the dictyostatin compounds can be used in the treatment of a number of diseases in which aberrant cellular proliferation occurs such as drug-sensitive and drug-resistant cancers, autoimmune disorders, and inflammatory diseases.
    Type: Grant
    Filed: February 6, 2003
    Date of Patent: January 13, 2004
    Assignee: Harbor Branch Oceanographic Institution, Inc.
    Inventors: Amy E. Wright, Jennifer L. Cummins, Shirley A. Pomponi, Ross E. Longley, Richard A. Isbrucker
  • Novel compositions and uses of dictyostatin compounds
    Publication number: 20030153615
    Abstract: Dictyostatin-1 has been found to stabilize microtubules and prohibit their depolymerization to free tubulin. Because of these activities, the dictyostatin compounds can be used in the treatment of a number of diseases in which aberrant cellular proliferation occurs such as drug-sensitive and drug-resistant cancers, autoimmune disorders, and inflammatory diseases.
    Type: Application
    Filed: February 6, 2003
    Publication date: August 14, 2003
    Inventors: Amy E. Wright, Jennifer L. Cummins, Shirley A. Pomponi, Ross E. Longley, Richard A. Isbrucker
  • Compounds and methods of use for treatment of neurogenic inflammation
    Patent number: 6589957
    Abstract: The subject invention pertains to compounds which are useful as anti-inflammatory agents and to compositions containing such compounds as active ingredients. The novel uses of the compounds relate to the anti-neurogenic inflammatory properties of the disclosed bis-heterocyclic compounds. Specifically exemplified herein are dragmacidin f, topsentin d, and topsentin e, and their salts, analogs, and derivatives.
    Type: Grant
    Filed: August 31, 2001
    Date of Patent: July 8, 2003
    Assignees: Harbor Branch Oceanographic Institution, Inc., Regents of the University of California
    Inventors: Amy E. Wright, Shirley A. Pomponi, Robert S. Jacobs
  • Synthetic compounds for treatment of inflammation
    Patent number: 6589975
    Abstract: Novel uses of biologically active bis-heterocyclic e.g. bis-indole alkaloid compounds which have improved activity are disclosed. Pharmaceutical compositions containing the compounds are also disclosed. Specifically, the novel utility pertains to the anti-immunogenic and neurogenic inflammatory properties exhibited by the bis-indole compounds and their analogs.
    Type: Grant
    Filed: August 5, 2002
    Date of Patent: July 8, 2003
    Assignees: The Regents of the University of California, Harbor Branch Oceanographic Inst.
    Inventors: Robert S. Jacobs, Claudia E. Moya, Amy E. Wright
  • Compositions and uses of dictyostatin compounds
    Patent number: 6576658
    Abstract: Dictyostatin-1 has been found to stabilize microtubules and prohibit their depolymerization to free tubulin. Because of these activities, the dictyostatin compounds can be used in the treatment of a number of diseases in which aberrant cellular proliferation occurs such as drug-sensitive and drug-resistant cancers, autoimmune disorders, and inflammatory diseases.
    Type: Grant
    Filed: February 26, 2001
    Date of Patent: June 10, 2003
    Assignee: Harbor Branch Oceanographic Institution, Inc.
    Inventors: Amy E. Wright, Jennifer L. Cummins, Shirley A. Pomponi, Ross E. Longley, Richard A. Isbrucker